International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin’s lymphoma

Autor:	N. M. Chowhan, Jerome B. Zeldis, Jonathan Polikoff, I. Esseessee, T. E. Witzig, R. Greenberg, Annette Ervin-Haynes, Craig B. Reeder, Myron S. Czuczman, Dennis Pietronigro
Rok vydání:	2008
Předmět:	Oncology Cancer Research medicine.medical_specialty Univariate analysis business.industry medicine.disease Lymphoma Non-Hodgkin's lymphoma Surgery Regimen Exact test Refractory Internal medicine medicine Rituximab business Lenalidomide medicine.drug
Zdroj:	Journal of Clinical Oncology. 26:8509-8509
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2008.26.15_suppl.8509
Popis:	8509 Background: Lenalidomide is active with manageable side effects in non-Hodgkin’s lymphoma (NHL). This study aims to confirm the activity, safety, and predictors of response previously reported for lenalidomide in patients with relapsed/refractory (r/r) aggressive NHL in an international setting. Methods: Patients with r/r aggressive NHL with measurable disease (≥2 cm) after ≥1 prior treatment regimen were eligible. Patients received 25 mg lenalidomide orally once daily on Days 1- 21 every 28 days and continued therapy as tolerated or until disease progression. Response and progression were evaluated using the IWLRC methodology. Predictors of response were investigated by univariate analyses using Fisher’s exact test. Results: As of August 25, 2007, 46 patients were eligible for response assessment and 79 for safety evaluation. Median age was 65 (21–84) years, 74% were male, and 96% had received prior rituximab. Median time from diagnosis was 2 (0.2–12) years and median number of prior treatment regim...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a958c700a9ef1caadc857f2cca6990cb https://doi.org/10.1200/jco.2008.26.15_suppl.8509 Zobrazit plný text záznamu